Researchers from KU Leuven and the Francis Crick Institute have pinpointed 27 novel genes thought to prevent cancer from forming. Their findings could help develop personalised cancer treatments that target these genes.
The rogue messengers can be detected in blood and this may lead to the development of a blood test to help identify patients more susceptible to treatment resistance
Clinical trials are fundamental to the development of new treatments for cancer, but annual accrual to studies worldwide is low, at an estimated at three to five percent.
Enzymes that are over-expressed in tumour tissues can be used to trigger the release of therapeutic payloads only at the cancer sites where they are needed
EurocanPlatform, an EU-funded network coordinated by Karolinska Institutet, held its last meeting in Brussels in November. The outcome was new collaborative ventures between cancer centres in Europe designed to transfer scientific discoveries from lab to clinic.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.